Skip to content
SQUEEZE!
RILYSI 41.7%Fee 112%SCORE 97+15.2%◆
BYNDSI 36.2%Fee 56%SCORE 94+12.3%◆
UPSTSI 28.1%Fee 31%SCORE 88+8.7%◆
STEMSI 31.0%Fee 68%SCORE 82+4.5%◆
GMESI 22.4%Fee 18%SCORE 78+6.4%◆
AMCSI 19.8%Fee 43%SCORE 72+3.1%◆
PLUGSI 24.5%Fee 23%SCORE 71-0.8%◆
SPCESI 21.0%Fee 29%SCORE 66-5.1%◆
CVNASI 14.6%Fee 8%SCORE 64-1.2%◆
NKLASI 18.6%Fee 45%SCORE 61+0.0%◆
CLOVSI 15.4%Fee 14%SCORE 58+2.0%◆
MARASI 17.9%Fee 6%SCORE 48-3.6%◆
AFRMSI 9.8%Fee 4%SCORE 46+5.2%◆
SOFISI 11.2%Fee 2%SCORE 42+1.4%◆
TSLASI 3.1%Fee 0%SCORE 22+0.9%◆
BBBYQSI 8.2%Fee 1%SCORE 18-12.0%◆
RILYSI 41.7%Fee 112%SCORE 97+15.2%◆
BYNDSI 36.2%Fee 56%SCORE 94+12.3%◆
UPSTSI 28.1%Fee 31%SCORE 88+8.7%◆
STEMSI 31.0%Fee 68%SCORE 82+4.5%◆
GMESI 22.4%Fee 18%SCORE 78+6.4%◆
AMCSI 19.8%Fee 43%SCORE 72+3.1%◆
PLUGSI 24.5%Fee 23%SCORE 71-0.8%◆
SPCESI 21.0%Fee 29%SCORE 66-5.1%◆
CVNASI 14.6%Fee 8%SCORE 64-1.2%◆
NKLASI 18.6%Fee 45%SCORE 61+0.0%◆
CLOVSI 15.4%Fee 14%SCORE 58+2.0%◆
MARASI 17.9%Fee 6%SCORE 48-3.6%◆
AFRMSI 9.8%Fee 4%SCORE 46+5.2%◆
SOFISI 11.2%Fee 2%SCORE 42+1.4%◆
TSLASI 3.1%Fee 0%SCORE 22+0.9%◆
BBBYQSI 8.2%Fee 1%SCORE 18-12.0%◆
← All briefs

2026-09-24

NTLA's 33% Short Interest Meets an FDA Catalyst

Not financial advice. Verify claims independently.

Intellia carries the highest biotech SI on our board — and a March 2027 PDUFA date on deck.

Intellia (NTLA) is running the classic biotech squeeze setup:

  • 33.3% short interest — one of the highest in the sector
  • 14.1 days to cover — shorts can't exit in a day if the news goes their way
  • Catalyst scheduled: FDA accepted the lonvo-z application for HAE with priority review; March 10, 2027 decision date
  • ARK bought 204k shares recently — institutional validation against the shorts

The asymmetric setup: high SI + scheduled binary catalyst + committed longs = the squeeze has both the fuel (shorts trapped) and the timeline (known date).

The counter: biotech catalysts cut both ways — FDA decisions are genuinely binary. The squeeze trade and the blowup trade look identical until the announcement.

Run both scenarios on Stock Picks.

Put it into practice

Rehearse this strategy risk-free on Stock Picks — the paper-trading app from the team behind SQUEEZE!.

Open Stock Picks →